KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Return on Equity (2016 - 2026)

Pacific Biosciences Of California has reported Return on Equity over the past 15 years, most recently at 0.26% for Q4 2025.

  • For Q4 2025, Return on Equity fell 26.0% year-over-year to 0.26%; the TTM value through Dec 2025 reached 0.26%, down 26.0%, while the annual FY2025 figure was 0.02%, 2.0% down from the prior year.
  • Return on Equity for Q4 2025 was 0.26% at Pacific Biosciences Of California, down from 0.1% in the prior quarter.
  • Over five years, Return on Equity peaked at 0.0% in Q1 2021 and troughed at 0.26% in Q4 2025.
  • A 5-year average of 0.03% and a median of 0.0% in 2023 define the central range for Return on Equity.
  • Biggest five-year swings in Return on Equity: grew 2bps in 2021 and later dropped -26bps in 2025.
  • Year by year, Return on Equity stood at 0.0% in 2021, then tumbled by -460bps to 0.01% in 2022, then grew by 21bps to 0.0% in 2023, then tumbled by -54bps to 0.01% in 2024, then plummeted by -3984bps to 0.26% in 2025.
  • Business Quant data shows Return on Equity for PACB at 0.26% in Q4 2025, 0.1% in Q3 2025, and 0.07% in Q2 2025.